MyFinsight
Home
Blog
About
Proceeds from exercise of
stock options
$1,287K
Net cash provided by
financing activities
$923K
Canceled cashflow
$364K
Net (decrease)
increase in cash and cash...
-$435,776K
Canceled cashflow
$923K
Share-based compensation
expense
$16,752K
Accounts payable
$2,609K
Depreciation and
amortization
$1,560K
Amortization of right-of-use
asset
$354K
Loss on disposal of
property and equipment
-$78K
Payment of offering
costs
$364K
Net cash used in
investing activities
-$316,369K
Net cash used in
operating activities
-$120,330K
Canceled cashflow
$21,353K
Purchases of marketable
securities
$302,177K
Purchases of in-process
research and development...
$9,014K
Purchases of property and
equipment
$5,178K
Net loss
-$126,966K
Prepaid expenses and
other assets
$11,995K
Accrued expenses and
other current...
-$1,843K
Accretion of discounts on
marketable securities
$446K
Operating lease
liabilities
-$433K
Back
Back
Cash Flow
Immunome Inc. (IMNM)
Immunome Inc. (IMNM)
source: myfinsight.com